Currently, adjuvant chemotherapy is not recommended for all patients with Stage II CRC in Japan; however, these results suggest that postoperative adjuvant chemotherapy should be considered for Stage II small-bowel cancer with SMAD4 mutations because of the high risk of recurrence. This evidence concerns the gene SMAD4 and small intestine carcinoma.